- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ZyVersa Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| ZYVERSA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.11.24 | ZVSA stock touches 52-week low at $1.03 amid sharp annual decline | 2 | Investing.com | ||
| 27.11.24 | ZVSA-Aktie erreicht 52-Wochen-Tief bei 1,03 US-Dollar | 9 | Investing.com Deutsch | ||
| 20.11.24 | ZyVersa reports progress on stroke-related heart injury treatment | 2 | Investing.com | ||
| 20.11.24 | ZyVersa meldet Fortschritte bei der Behandlung von schlaganfallbedingten Herzschäden | 4 | Investing.com Deutsch | ||
| 20.11.24 | ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial | 1 | GlobeNewswire (USA) | ||
| 14.11.24 | ZyVersa Therapeutics GAAP EPS of -$2.43 misses by $0.83 | 1 | Seeking Alpha | ||
| 14.11.24 | ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update | 115 | GlobeNewswire (Europe) | KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic & Inflammatory Disease... ► Artikel lesen | |
| 14.11.24 | ZyVersa Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.24 | ZyVersa Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.11.24 | ZVSA stock plunges to 52-week low, hitting $1.34 amid market challenges | 1 | Investing.com | ||
| 05.11.24 | ZyVersa reports progress on obesity inflammation treatment | 4 | Investing.com | ||
| 05.11.24 | ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes | 1 | GlobeNewswire (USA) | ||
| 30.10.24 | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.10.24 | ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs | 1 | GlobeNewswire (USA) | ||
| 22.10.24 | ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases | 1 | GlobeNewswire (USA) | ||
| 17.10.24 | ZyVersa macht Fortschritte bei Medikament gegen Fettleibigkeit mit wichtigen Meilensteinen in Aussicht | 6 | Investing.com Deutsch | ||
| 17.10.24 | ZyVersa advances obesity drug with key milestones ahead | 5 | Investing.com | ||
| 17.10.24 | ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months | 87 | GlobeNewswire (Europe) | Lead indication for ZyVersa's Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications. WESTON, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA,... ► Artikel lesen | |
| 15.10.24 | ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 50,76 | 0,00 % | Der neue KI-Star: Cathie Wood und Nancy Pelosi haben schon zugegriffen - Tempus AI wird zum Muss! | © Foto: Gorodenkoff / Stock.adobe.comAufgepasst Siri und Alexa! Olivia, die KI-gestützte Gesundheits-Concierge-App von Tempus AI, ist auf dem Weg. Allein ihre Ankündigung bescherte Tempus AI den besten... ► Artikel lesen | |
| SILEXION THERAPEUTICS | 3,135 | 0,00 % | Pre-market Movers: Silexion Therapeutics, Zentalis Pharmaceuticals, 60 Degrees Pharmaceuticals, Manhattan Associates, Nextracker | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Silexion Therapeutics Corp (SLXN) is up over 65%... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,155 | 0,00 % | Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.6% - Here's Why | ||
| VERA THERAPEUTICS | 37,890 | +5,31 % | Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's What Happened | ||
| 89BIO | 8,730 | -3,05 % | 89bio, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 30,660 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer | SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 31,960 | -0,37 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen | |
| IMMUNOVANT | 21,805 | -1,02 % | Immunovant (NASDAQ:IMVT) Sets New 12-Month Low on Insider Selling | ||
| SUMMIT THERAPEUTICS | 21,630 | 0,00 % | Why Summit Therapeutics (SMMT) Is Skyrocketing Now | ||
| ZENTALIS PHARMACEUTICALS | 1,900 | 0,00 % | Zentalis Pharmaceuticals Stock Plunges After 40% Workforce Cut Announcement | ||
| ADMA BIOLOGICS | 16,390 | +1,36 % | EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot? | WASHINGTON (dpa-AFX) - Biotech investing is a high-stakes game that may not suit the faint-hearted due to its inherent volatility. However, this sector can offer astronomical returns when investors... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 36,550 | 0,00 % | Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A | Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancersFinancials include a $13 million upfront payment and potential... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,900 | 0,00 % | Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews | ||
| NUVALENT | 85,69 | 0,00 % | Nuvalent-Direktor Matthew Shair verkauft Aktien im Wert von 165.575 US-Dollar | ||
| EDGEWISE THERAPEUTICS | 28,460 | +2,26 % | Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now? |
ZYVERSA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,340 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZYVERSA THERAPEUTICS INC finden Sie auf Wallstreet Online.
